Results 121 to 130 of about 15,740 (203)

Prussian Blue Nanozyme Potentiates Venetoclax Efficacy in Acute Myeloid Leukemia by Inducing a More Mature Phenotype. [PDF]

Int J Nanomedicine
Yang F, Wu H, Yao J, Peng X, Yang A, Wen T, Meng J, Liu J, Zhang Y, Wang T, Xu H.   +10 more
europepmc   +1 more source

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax. [PDF]

Front Oncol
Chen F, Wang Y, Fu Z, Chang L, Jiang X, Zhang Z, Li C, Liu L, Yang L.   +8 more
europepmc   +1 more source

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. [PDF]

Blood Adv
Castonguay M, Anderson MA, Thompson P, Seymour JF.   +3 more
europepmc   +1 more source

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. [PDF]

Hemasphere
Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, Xie J, Vlachos S, Hunter SM, Gonzales J, Binks S, Seymour JF.   +11 more
europepmc   +1 more source

The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia

HemaSphere, Volume 10, Issue 8, August 2026.
Zahra Sheybani, Charles E. de Bock
wiley   +1 more source

Novel treatment strategies in acute myeloid leukemia. [PDF]

Blood Res
Simkhada S, Joshi U, Dhakal P.
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, Volume 209, Issue 2, Page 534-543, August 2026.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +1 more source

Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. [PDF]

Signal Transduct Target Ther
Aboelella NS, Park R, Tang E, Asby N, Ho JD, Pan T, Wang S, Xie L, Kline JP, Riedell PA, Huang J, LaBelle JL.   +11 more
europepmc   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

Cancer Science, Volume 117, Issue 8, Page 2050-2063, August 2026.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah, Mackenzie M. Mayhew, Jacob Sellers, Russell G. Witt   +3 more
wiley   +1 more source